表3.

既往辅助系统治疗后的全身治疗方案

Agents	Target population
Osimertinib 80 mg daily	Osimertinib for patients with completely resected stage IB-IIIA or stage IIIB (T3, N2) NSCLC and positive for EGFR mutations (exon 19 deletion, exon 21 L858R mutations) who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy
Atezolizumab 840 mg every 2 weeks, 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks for up to 1 year	Atezolizumab for patients with completely resected stage IIB-IIIA, stage IIIB (T3, N2), or high-risk stage IIA NSCLC with PD-L1≥1% and negative for EGFR exon 19 deletion or exon 21 L858R mutations or ALK rearrangements who received previous adjuvant chemotherapy and with no contraindications to immune checkpoint inhibitors
Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks for up to 1 year	Pembrolizumab for patients with completely resected stage IIB-IIIA, stage IIIB (T3, N2), or high-risk stage IIA NSCLC and negative for EGFR exon 19 deletion or exon 21 L858R mutations or ALK rearrangements who received previous adjuvant chemotherapy and with no contraindications to immune checkpoint inhibitors

NSCLC: non-small cell lung cancer; EGFR: epidermal growth factor receptor; PD-L1: programmed cell death ligand 1; ALK: anaplastic lymphoma kinase.